Study Completed

Contraception, Ovulation Inhibition, Contraceptives, Oral

Bayer Identifier:

91062

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available

Study to assess efficacy and safety of Yasmin in an extended cycle regimen

Trial purpose

Please see attached Study Results Summary below.

Key Participants Requirements

Sex

N/A

Age

N/A

Trial summary

Enrollment Goal

184

Trial Dates

May 2002 - January 2004

Phase

Phase 4

Could I Receive a placebo

N/A

Products

Yasmin (EE30/DRSP, BAY86-5131)

Accepts Healthy Volunteer

N/A

Primary Outcome

Secondary Outcome

Trial design

Prospective, multi-center, open, uncontrolled study to investigate the efficacy, safety and acceptance of SH T 470 FA (Yasmin® [30μg ethinylestradiol and 3mg drospirenone]) in an extended cycle regimen of up to 36 weeks for oral contraception in 200 female volunteers

Trial Type

Interventional

Intervention Type

N/A

Trial Purpose

N/A

Allocation

N/A

Blinding

N/A

Assignment

N/A

Trial Arms

N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to marketed products.